MRNAModerna, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 18751
Ticker: MRNA
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2018-12-07
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: MRNA

Detail

Enriched 2026-08-14 20:47

Market cap: $25,419,349,052.63
Shares outstanding (class): 399,235,889
Shares outstanding (weighted): 399,235,889
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 4,700
Location: CAMBRIDGE, MA
Homepage: https://www.modernatx.com
Description: Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Market cap and share counts drift.

Funds holding this security

291 funds · 298 positions · $4.11B reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$573.83M	0.03%	11,295,961 NS	FIGI
VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS	VOO	$448.98M	0.03%	8,838,135 NS	FIGI
VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS	VB	$416.35M	0.25%	8,195,823 NS	FIGI
VANGUARD SMALL-CAP VALUE INDEX FUND VANGUARD INDEX FUNDS	VBR	$265.13M	0.44%	5,219,030 NS	FIGI
iShares Core S&P 500 ETF iShares Trust	IVV	$227.22M	0.03%	4,472,808 NS	FIGI
N/A —	—	$205.82M	0.03%	4,051,659 NS	FIGI
Growth Fund AMERICAN FUNDS INSURANCE SERIES	—	$203.20M	0.41%	4,000,000 NS	FIGI
Fidelity Contrafund Fidelity Contrafund	—	$174.48M	0.11%	3,434,606 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$136.78M	1.68%	2,692,459 NS	FIGI
State Street(R) Health Care Select Sector SPDR(… SELECT SECTOR SPDR TRUST	XLV	$128.56M	0.33%	2,530,630 NS	FIGI
First Trust NYSE Arca Biotechnology Index Fund First Trust Exchange-Traded Fund	FBT	$119.45M	5.26%	2,351,289 NS	FIGI
VANGUARD INSTITUTIONAL INDEX FUND VANGUARD INSTITUTIONAL INDEX FUNDS	—	$99.48M	0.03%	1,958,337 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$76.90M	1.03%	1,513,720 NS	FIGI
iShares Russell Mid-Cap ETF iShares Trust	IWR	$69.47M	0.14%	1,367,541 NS	FIGI
VIP Growth Portfolio Variable Insurance Products Fund	—	$57.15M	0.54%	1,125,011 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERMRNA
FIGI_COMPOSITEBBG003PHHZT1
FIGI_SHARE_CLASSBBG003PHHZV8
CIK0001682852
ISINUS60770K1079
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Moderna is a biotechnology company focused on mRNA-based therapeutics and vaccines.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.